LNA Santé (LNA) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
24 Sep, 2026Executive summary
Achieved a solid first half in a politically and economically unstable environment, confirming full-year 2026 guidance for activity growth and improved results.
Operating revenue for H1 2026 reached €465.1m, up 8.0% year-over-year, with organic growth of 7.0%, surpassing initial guidance.
Net profit attributable to the Group from operations was €14.9m, up 8.3% year-over-year, with a margin of 3.2%.
All business lines grew, driven by ambulatory services and higher occupancy in EHPADs, with total revenue at €484.0m, up 8.4% year-over-year.
Continued transformation of the network, with 86% of the installed capacity now in mature 'régime de croisière' status.
Financial highlights
Consolidated revenue for H1 2026: €484.0m (+8.4% YoY), with Exploitation revenue at €465.1m (+8.0% YoY, +7.0% organic).
EBITDA: €81.1m (+3.7% YoY), margin 16.7% (-76bps YoY); EBITDA excl. IFRS 16: €42.1m (+3.3% YoY), margin 8.7% (-43bps YoY).
Net income (group share): €12.5m (+10.6% YoY), net margin 2.6% (+5bps YoY).
Operating EBITDA (excluding IFRS 16) was €38.1m, up 3.6%, with a margin of 8.2%, slightly down due to restructuring costs.
Net debt: €412.4m (up €23.6m from Dec 2025); available cash: €89.3m.
Outlook and guidance
2026 organic revenue growth target raised to 6% (from 5%), with Exploitation revenue expected near €930m.
EBITDA margin (excl. IFRS 16) for mature sites expected to remain 10–10.5% for H2 2026.
Free cash flow target revised to €40–45m for 2026 due to intensified restructuring and higher Capex.
Leverage expected to remain below 2.0x at year-end, barring new acquisitions.
Strategic plan targets €1bn revenue by 2027 and €1.25bn by 2031, with a mature network of 13,000+ beds.
Latest events from LNA Santé
- H1 2024 revenue up 8.2% to €386.3m, with robust organic growth and high occupancy rates.LNA
Q2 2024 TU - Revenue up 8.2%, net profit up 5.1%, and leverage improved to 1.69x.LNA
H1 2024 - Nine-month revenue up 9.1% with robust growth in home-based care and high occupancy rates.LNA
Q3 2024 TU - Sales up 10.3% to €793.9m, with 2025 guidance at €845m and 6% organic growth.LNA
H2 2024 - 2024 revenue rose 10.3% to €793.9m, driven by outpatient and homecare growth.LNA
Q4 2024 TU - Q1 2025 delivered 8.9% organic sales growth, led by outpatient care and real estate momentum.LNA
Q1 2025 TU - H1 2025 revenue grew 9.1% pro forma, with 2025 guidance raised to €860 million.LNA
Q2 2025 TU - Strong revenue and EBITDA growth in H1 2025, with ambitious targets confirmed for 2025 and 2031.LNA
H1 2025 - Revenue up 11.4% year-over-year, real estate rebounds, 2025 targets reaffirmed.LNA
Q3 2025 TU